by Michelle Edwards at UncoverDC
As COVID-19 vaccines—including Moderna and Pfizer-NBioTech’s mRNA “gene-therapy” jabs—continue to be promoted and mandated as the primary “treatment” against SARS-CoV-2, other alternative therapies have been around for just as long as the vaccines but have been heavily censored by government agencies. With substantial funding from the U.S. Defense Department’s Advanced Research Projects Agency (DARPA) since 2011, mRNA vaccine technology took center stage as a treatment for COVID, with both mRNA “vaccines” receiving Emergency Use Authorization (EUA). Still, one element missing from the emerging treatment was clinical proof of its effectiveness.
Despite Years of Study, mRNA Vaccines Lacked Trial on Large Scale
A 2017 article published in Nature called “The ‘anti-hype’ vaccine” starts by remarking that the idea of “vaccines-on-demand” is an “alluring, yet misleadingly simple, concept,” adding that “such a vaccine would enable rapid-response agents against pandemic threats.” Ignored for years, using RNA as a starting point for immunotherapy “ticks many of the boxes for a vaccine-on-demand offering advantages in manufacture, flexibility, scalability, and cost of goods.” Nonetheless, clinical validation faced challenging obstacles, “such as antigen discovery, product formulation, and delivery.”
The first mRNA vaccine to be injected into humans was a prostate cancer product developed by CureVac. Despite $110 million in funding from Bill Gates and German billionaire Dietmar Hopp in 2015, the product failed to improve survival over the standard of care in patients with prostate cancer. With sustained interest across the board—including the commitment from DARPA, specifically its Biological Technology Office (BTO) in D.C.— the failure of Curevac’s mRNA prostate vaccine didn’t stop funding, and research continued. At the time, Matt Hepburn, program manager at DARPA’s BTO, whose primary focus is having “platforms in place that can respond quickly in the case of a pandemic,” commented:…
Continue Reading